This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Atherosclerosis

Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Sponsored by Zibo Central Hospital

About this trial

Last updated 4 years ago

Study ID

ZiboCH

Status

Unknown status

Type

Observational

Placebo

No

Accepting

18-75 Years
18 to 85 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 3 years ago

What is this trial about?

Compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. This study is going to investigate the change of lesion-specific hemodynamic significance as determined by ML(Machine Learning)-based CT-FFR (Computed Tomography-Fractional Flow Reserve)after Evolocumab treatment.

What are the participation requirements?

Yes

Inclusion Criteria

- 1.baseline CCTA revealed at least one lesion with stenotic extent from 50% to 69% on major epicardial arteries (diameter ≧2 mm);

- 2.patients were referred for optimal medical treatment;

- 3.patients agreed to undergo follow-up CCTA at 1-year interval.

No

Exclusion Criteria

- 1.patients had previous history of myocardial infarction or coronary revascularization;

- 2.patients were contraindicated to the usage of iodine contrast media;

- 3.image quality of baseline or follow-up CCTA was severely impaired (in presence of severe artifact, non-diagnostic);

- 4.patients withdrew the informed consents during follow-up;

- 5.patients experienced major adverse cardiac events during follow-up;

- 6.patients refused to undergo follow-up CCTA;

- 7.lost follow-up

Locations

Location

Status